deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03732638

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention

Sponsor: Pfizer

Conditions Migraine
Interventions Placebo Rimegepant
Updated 19 times since 2018 Last updated: May 23, 2024 Started: Nov 14, 2018 Primary completion: Dec 10, 2019 Completion: Feb 2, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03732638, this PHASE2/PHASE3 trial focuses on Migraine and remains completed. Sponsored by Pfizer, it has been updated 19 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Dec 2020 · 7 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Dec 2022 · 15 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Mar 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2023 — Mar 2023 [monthly]

    Completed PHASE2_PHASE3

▶ Show 14 earlier versions

  1. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2_PHASE3

  2. Sep 2021 — Dec 2022 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  3. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  5. May 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  6. Jan 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  7. Nov 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  8. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE2_PHASE3

  10. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2_PHASE3

  11. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2_PHASE3

  12. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE2_PHASE3

  13. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2_PHASE3

  14. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Anaheim, United States , Anderson, United States , Ann Arbor, United States , Apple Valley, United States , Austin, United States , Bellevue, United States , Berlin, United States , Biloxi, United States , Boise, United States and 79 more locations